

INDEX

PHARMACOLOGICAL REVIEWS

Volume 23

1971

- Actomyosin
 cardiac glycosides influence on
 ATPase activity, 209
 "contractile" behavior, 209
 viscosity of, 208
- Adrenal cortex and medulla. (*See also*
 Adrenal medulla)
 anatomic relationship, 2, 5
 functional consequences of juxtaposition,
 2
 functional interactions, 2
- Adrenal cortical and chromaffin cells
 association in
 amphibians, 10
 fish, 10
 vertebrate species, 10
- Adrenal medulla. (*See also* Adrenal cortex
 and medulla)
 chromaffin cells. (*See* Chromaffin cells)
 circulation, comparative anatomy of, 11
 effects of
 glucocorticoids, 18
 hypophysectomy, 18
 epinephrine- and norepinephrine-con-
 taining cells, variation among
 species, 11
 evolution in mammal, 9
 innervation
 age variation among species, 22
 segmental distribution, 6
 morphological changes after hypophysec-
 tomy, 19
 selective secretion of epinephrine and
 norepinephrine, 24
 vascular supply, 12
- d*-Amphetamine effects on threshold to
 electrical stimulation in animals
 with indwelling brain electrodes
 (tables), 325, 326
- Atelectasis, 42
- Axelrod, Julius. (*See* Lemberger, Axelrod
 and Kopin), 371
- Cannabichromene
 occurrence in marihuana, 270
- Cannabicyclol
 occurrence in marihuana, 269
- Cannabidiol
 occurrence in marihuana, 268
- Cannabigerol
 occurrence in marihuana, 269
- Cannabinol
 occurrence in marihuana, 269
- Cannabinoids, 269
 definition, 273
- Cannabis. (*See also* Δ^8 - and Δ^9 -Tetrahydro-
 cannabinol and Marihuana)
 dose-response relationships in human
 subjects, 339-347
 effect on barbiturate-induced sleeping
 time, 306
 oral ingestion and inhalation of smoke,
 pharmacological difference in, 339
 resin extract, hypothermic effect, 308
 tincture of, hypothermic effect, 309
 tolerance development in rats, 311
- Cannabis sativa*. (*See also* Marihuana)
 active principles of, 285
 extract of, 266
 source for manicured marihuana, 267
- Carbon dioxide
 role in pulmonary oxygen toxicity, 96
- Cardiac function
 cardiac glycosides action on, 196
- Cardiac glycosides
 action on
 contractile proteins, 207
 nonfailing heart, 194
 binding on Na⁺-K⁺ ATPase, 224
 [Ca⁺⁺]_o-dependence of action, 200
 cardiotonic factor, prevention of loss of,
 203
 catecholamines released by, 202
 effect on
 electrophysiological properties of the
 myocardium, 227
 excitation-contraction coupling, 233
 myocardial potassium and sodium
 content, 215

- Cardiac glycosides—(*Continued*)
- Na⁺-K⁺ ATPase, 221
 - sarcoplasmic reticulum, 236
 - frequency-dependence of action
 - magnitude of effect, 197
 - onset of action, 196
 - heart muscle, localization in, 203
 - subcellular distribution in, 204
 - uptake in, 204
 - influence on
 - action potential, 229
 - actomyosin ATPase activity, 209
 - “contractile” behavior of actomyosin preparations, 209
 - contractile mechanics of heart muscle, 195
 - diastolic membrane potential of myocardial cells, 228
 - enzymatic properties of myosin, 208
 - glycerol-extracted muscle preparations, 210
 - intracellular calcium distribution, 241
 - inward calcium current, 235
 - mechanical threshold, 235
 - myocardial calcium metabolism, 239
 - myocardial energy metabolism, 210
 - physicochemical properties of myosin, 208
 - polymerization of g-actin, 207
 - potassium efflux from heart muscle, 217
 - transmembrane potassium and sodium turnover, 219
 - viscosity of actomyosin, 208
 - inhibition of Na⁺-K⁺ ATPase, 221
 - inotropic action
 - digitalis effects, 202
 - subcellular basis for mechanism of, 193-261
 - interaction between Na⁺-K⁺ ATPase and, 224
 - myocardial uptake, influencing factors, 206
 - potassium-dependence of action, 198
 - sodium-dependence of action, 199
 - stimulation of Na⁺-K⁺ ATPase, 225
- Catecholamines. (*See also* Epinephrine, Norepinephrine)
- Catecholamines
- enzymes involved in metabolism of, 18
 - release by
 - acetylcholine, 25
 - brain stimulation, 24
 - cardiac glycosides, 202
 - stimulation of splanchnic nerves, 25
 - release during insulin-induced hypoglycemia, 26
 - role in indirect inotropic effect of cardiac glycosides, 202
- Catecholamine synthesis (*See also* Epinephrine synthesis)
- chromaffin cells, 6, 7
 - enzymes involved in, 18
 - postganglionic sympathetic neurons, 7
 - rate control, 7
 - tyrosine hydroxylation, 7
- Central nervous system
- actions of synthetic tetrahydrocannabinol derivatives, 317-336
 - effects of
 - DMHP interactions with other drugs, 306
 - DMHP, MOP, and NAP, 298
 - tetrahydrocannabinols, 285, 292
 - interaction with pulmonary effects of oxygen poisoning, 82
 - protection from pulmonary oxygen poisoning by anesthetics, 82
- Chromaffin cells
- adult mammal, 4
 - catecholamine biosynthesis, 6
 - chromaffin granules, 5
 - chromaffin reaction, 4
 - distribution in
 - birds, 10
 - mammals, 10
 - reptiles, 10
 - ungulates, 11
 - histology of, 4
 - innervation of, 5
- Clark, J. M., and C. J. Lambertsen. Pulmonary oxygen toxicity: a review, 37
- Digitalis
- effect on movement of myocardial potassium and sodium, 215
 - role in indirect inotropic effect of cardiac glycosides, 202
- DMHP
- analgesic properties, 317
 - methods to determine, 317
 - behavioral responses, 298
 - cardiovascular responses to (table), 299
 - cross tolerance with morphine, 311
 - dose-effect relationships, 339
 - drug interactions
 - d-amphetamine, 306

- behavioral interactions in the dog,
306; (table), 307
- caffeine, 306
- cocaine, 306
- nalorphine, 306
- effect on
- avoidance behavior
 - dog conditioned, 317
 - monkey two-way shuttle box, 317
 - rat pole jump, 317
 - barbiturate-induced sleeping time, 305
 - cerebral electrical activity in animals,
326, 325
 - common carotid occlusion pressor re-
flex, 300; (table), 301
 - conditioned behavior, 317
 - electrical correlates of conditioned
avoidance response in the dog, 317
 - high spinal cats, 317, 332
 - patellar reflex
 - bulbar facilitation of, 317, 333
 - inhibition of, 317, 333
 - photic driving of electroencephalogram
of dog, 317, 329
 - spinal reflexes, 317
 - threshold for response to electrical
stimulation of amygdala, 325, 326
 - threshold for stimulation of posterior
hypothalamus, 325, 326
 - threshold to stimulation in animals
with indwelling brain electrodes,
325, 322, 326; (tables), 325, 326
 - threshold to stimulation of brainstem
reticular formation, 325, 326
- electroencephalographic effects and par-
tial antagonism by methylpheni-
date in monkey with indwelling
brain electrodes, 323
- hypotensive potency, 299; (table), 300
- hypothermic effects, 308
- hypothermic response, 309
- pharmacological activity, 299
- pharmacological comparison of old vs.
new samples (table), 298
- pharmacological potency and efficacy, 296
- reserpine and, similarities of pharma-
cological actions, 306
- solubility of, 297
- structural formula, 296
- tolerance development, 310-311
- dogs, 310
 - monkeys, 310
- treatment of essential hypertension, 305
- Domino, Edward F., Harold F. Hardman
and Maurice H. Seevers. Central
nervous system actions of some
synthetic tetrahydrocannabinol de-
rivatives, 317
- Domino, Edward F. (*See* Hardman, Domino
and Seevers), 295
- Epinephrine. (*See also* Catecholamines)
effects of hypophysectomy and gluco-
corticoids, 18
- isotopically labeled, recovery from
adrenals, 8
- secretion from adrenal medulla, 24
- Epinephrine synthesis
adrenal medulla, 2
- adrenocortical control, 1-35
- Forney, Robert B. Toxicology of marihuana,
279
- Gas exchange
pulmonary oxygen poisoning, 58
- Gibbins, R. J. (*See* Kalant, LeBlanc and
Gibbins), 135
- Glucocorticoid concentration
relationship with phenylethanolamine-
N-methyl transferase activity, 22
- Glucocorticoids
effects of
hypophysectomy and hormones on
concentrations in blood, 16
- suppression on epinephrine, 3
- extra-adrenal
adult, 21
- fetus, 20
- influence on
epinephrine biosynthesis, 2
- phenylethanolamine-N-methyl trans-
ferase, 2
- Glycosides, cardiac. (*See* Cardiac glyco-
sides)
- Hardman, Harold F., Edward F. Domino
and Maurice H. Seevers. General
pharmacological actions of some
synthetic tetrahydrocannabinol de-
rivatives, 295
(*See* Domino, Hardman and Seevers),
317
- Harris, Louis S. General and behavioral
pharmacology, 285
- Hashish
 Δ^9 -tetrahydrocannabinol content, 371
- Heart. (*See also* entries beginning with
Cardiac)
nonfailing, cardiac glycosides action, 194

- Heart muscle**
 cardiac glycosides
 action on
 contractile mechanics, 195
 contractile proteins, 207
 effect on
 electrophysiological properties, 227
 potassium and sodium content, 215
 influence on
 action potential, 229
 calcium metabolism, 239
 diastolic membrane potential, 228
 electrolyte metabolism, 219
 energy metabolism, 210
 potassium efflux from, 217
 localization in, 203
 subcellular distribution of, 204
 uptake of, 204
 effect of digitalis on potassium and sodium, 215
 Na⁺-K⁺ ATPase inhibitors with no inotropic effects, 227
- Hollister, Leo E. Actions of various marihuana derivatives in man, 349
- Hyaline membranes**
 pulmonary. (*See under* Pulmonary oxygen toxicity)
- 1-Hydroxy-3(1,2-dimethylheptyl)-6,6,9-trimethyl 7,8,9,10-tetrahydro-6-dibenzopyran. (*See* DMHP)
- 1-Hydroxy-3-(n-amyl)-6,6,9-trimethyl 7,8,9,10-tetrahydro-6-dibenzopyran. (*See* NAP)
- 1-Hydroxy-3-(secondary nonyl)-6,6,9-trimethyl 7,8,9,10-tetrahydro-6-dibenzopyran. (*See* MOP)
- Hyperoxia**
 adrenocortical response, 76
- Hypoxemia**
 pulmonary oxygen poisoning, 60
- Isbell, Harris. Clinical pharmacology of marihuana, 337
- Jones, Reese T. Marihuana-induced "high": influence of expectation, setting and previous drug experience, 359
- Kalant, H., A. E. LeBlanc and R. J. Gibbins. Tolerance to, and dependence on, some non-opiate psychotropic drugs, 135
- Kiplinger, Glenn F., and Joseph E. Manno. Dose-response relationships to cannabis in human subjects, 339
- Klaus, Wolfgang. (*See* Lee and Klaus), 193
- Kopin, Irwin J. (*See* Lemberger, Axelrod and Kopin), 371
- Lambertsen, C. J. (*See* Clark and Lambertsen), 37
- LeBlanc, A. E. (*See* Kalant, LeBlanc and Gibbins), 135
- Lee, Kwang S. and Wolfgang Klaus. The subcellular basis for the mechanism of inotropic action of cardiac glycosides, 193
- Lemberger, Louis, Julius Axelrod and Irwin J. Kopin. Metabolism and disposition of Δ -tetrahydrocannabinol in man, 371
- Lungs.** (*See also* entries beginning with Pulmonary)
 biochemical changes during oxygen poisoning, 103
 mitochondrial changes, 48
 toxic effects of oxygen, 39
- Lung volumes**
 oxygen poisoning effect on vital capacity, 57
- Manno, Joseph E. (*See* Kiplinger and Manno), 339
- Marihuana.** (*See also* Cannabis, *Cannabis sativa*, and Δ^8 - and Δ^9 -Tetrahydrocannabinol)
 absorption, 274
 analysis, 269
 drug-type (table), 267
 hemp-type (table), 267
 and surrogates, 263-380
 cannabichromene and its derivative in, 270
 cannabicyclol occurring in, 269
 cannabidiol and its derivatives in, 268
 cannabinol and its derivatives in, 269
 cannabigerol and its derivatives in, 269
 cannabis prelude, 263
 chemistry of, 265-271
 comparison of
 cumulative excretion of radioactivity after injection of ¹⁴C- Δ^9 -THC, 376
 placebo and subjective symptoms (table), 366
 comparison with ethanol
 oral dose, 354, 355
 smoked dose, 355

- derivatives
 actions in man, 349-357
- dose-effect relationship
 performance parameters, 339
 physiological parameters, 339
- effects of
 setting on mood, 359
 "socially relevant" doses, 360
- frequent and infrequent users
 changes in performance measures
 (table), 364
 changes in physiological measures
 (table), 564
 level of intoxication (table), 564
- gas chromatogram, 266
- global intoxication ratings, 359; (table), 364
- intoxication level produced in experienced user, 539
- manicured, for use and extraction, 267, 268
- objective changes in man, 337
- oral consumption, 274
- pharmacology of, 263-380
 clinical, 337-338
- placebo and
 level of intoxication (tables), 361, 364
 syndromes from smoking (table), 354
- smoking studies, 273
- subjective drug effects
 group setting (table), 367
 solitary setting (table), 367
- subjective mental effects, 337
- subjective response after smoking a placebo, 359
- Δ^9 -tetrahydrocannabinol and its derivatives in, 268
- Δ^9 -tetrahydrocannabinol content of, 371
- tolerance. (*See also* under Tetrahydrocannabinol, Δ^9 -)
 pharmacological, 359
 toxicology of, 279-284
- Marihuana-induced "high"
 influence of
 expectation, 359
 previous drug experience, 359
 setting, 359
- Marihuana smoke
 Δ^9 -tetrahydrocannabinol distribution in, 274
- Methylphenidate antagonism
 effects on threshold to electrical stimulation in animals with indwelling brain electrodes (tables), 325, 326
- MOP
 behavioral responses, 298
 pharmacological activity, 299
 solubility of, 297
 structural formula, 297
- Myosin
 cardiac glycosides influence on, 208
- Na^+ - K^+ ATPase
 cardiac glycosides
 binding on, 224
 inhibition of, 221
 interaction with, 224
 stimulation by, 225
 influence of erythropleum alkaloids, 227
 inhibitors without inotropic effects on heart muscle, 227
- NAP
 behavioral responses, 298
 effects on common carotid occlusion pressor reflex, 300; (table), 301
 hypotensive potency, 299; (table), 300
 pharmacological activity, 299
 solubility of, 297
 structural formula, 296
- Norepinephrine. (*See also* Catecholamines)
 secretion from adrenal medulla, 24
- Oxygen
 physiological effects, 38
 toxic effects, 38
 direct, 79
 on lung, 39
- Oxygen tolerance
 pulmonary. (*See* Pulmonary oxygen tolerance)
- Oxygen toxicity
 pulmonary (*See* Pulmonary oxygen toxicity)
- Phenylethanolamine-N-methyl transferase (PNMT)
 aminoglutethimide effects on activity of, 15
 control of activity in man, 27
 dose-response characteristics, 15
 effects of
 chronic stresses, 13
 hibernation, 13
 extra-adrenal
 adult, 21
 fetus, 20
 function of, 2
 hormonal specificity, 13

- Phenylethanolamine-N-methyl transferase
—(Continued)
- hormone-induced alterations in epinephrine content of adrenal glands (table), 14
 - phenylethanolamine-N-methyl transferase activity in adrenal gland (table), 14
 - hypophysectomy effects on, 3
 - inducibility of isozymes, 19
 - induction by glucocorticoids, 12
 - inhibition of activity, 9
 - mechanisms of increased activity, 17
 - ontogenesis in adrenals, 21
 - role of glucocorticoids, 21
 - relationship between glucocorticoid concentration and PNMT activity, 22
 - substrate specificity, 8
 - synthesis, 2
- Pohorecky, Larissa A., and Richard J. Wurtman. Adrenocortical control of epinephrine synthesis, 1
- Proteins
- contractile, action of cardiac glycosides, 207
- Psychotropic drugs (non-opiate)
- absorption, 141
 - changes during chronic treatment, 141
 - dependence, 160–191
 - dependence
 - concept of redundancy, 169
 - cross-dependence, 167
 - definition, 160
 - denervation supersensitivity hypothesis, 168
 - measurement, 165
 - physical, 163
 - biochemical mechanisms, 171
 - physiological mechanisms, 169
 - signs and symptoms, 163
 - specific cellular mechanisms, 169
 - physiological mechanism, 169
 - psychological, 160
 - relation to drug load, 165
 - relation to tolerance, 166
 - dependence mechanisms
 - hypothetical models, 167
 - distribution, 141
 - altered, significance of, 143
 - change during chronic treatment, 141
 - excretion, 141
 - change during chronic treatment, 141
 - metabolism, 143
 - changes in pathways, 146
 - microsomal mixed function oxidase system, 147
 - rate of, 143
 - significance of increased rate of, 145
 - tolerance, 137–159
 - acquired change, 137
 - acute, 147, 148
 - changes in dose-response, curves, 153
 - chronic, 147, 151
 - concept of redundancy, 169
 - cross-tolerance, 159
 - definition, 137
 - denervation supersensitivity hypothesis, 168
 - development in animals and man (table), 155
 - dispositional, 137, 141
 - duration and carry-over, 156
 - effect of drug dose, 154
 - extent, 152
 - functional, 137, 147
 - generalization, 157
 - identification of type, 140
 - initial, 137
 - kinetic formulations, 174
 - “learned”, 158
 - mathematical formulations, 174
 - measurement techniques, 137–140
 - physiological, 158
 - physiological mechanism, 169
 - psychological (learned), 158
 - relation between acute and chronic, 174
 - specific cellular mechanisms, 169
 - speed of production, 151
 - tolerance mechanisms
 - hypothetical models, 167
 - withdrawal reactions, 163–165
- Pulmonary edema. (See under Pulmonary oxygen toxicity)
- Pulmonary oxygen tolerance
- adrenocortical response to hyperoxia, 76
 - immaturity associated with, 78
 - in animals, 64, 65; (table), 66
 - in animals exposed to 0.9–1.0 atm of oxygen (tables), 40, 41
 - in man, 68, (table), 70, 72, 73
 - intermittent interruption of oxygen breathing, 112
 - metabolic basis for acquired tolerance, 76
 - modification of, 109–114
 - nutritional factors, 77, 79
 - vital capacity as quantitative index, 69
- Pulmonary oxygen toxicity, 37–133
- adrenergic blocking agents, 87

- arterial P_O₂ influence, 81
 atelectasis, 42
 biochemical changes in lungs, 103
 biochemical effects, 79
 carbon dioxide
 acid-base factors, 99
 narcotic influence, 97
 role, 96
 central nervous system
 interaction with pulmonary effects, 82
 protection by anesthetics, 82
 drugs to delay onset or decrease severity, 111
 effects of
 enzyme and cofactor inactivation, 105
 histamine, 104
 irradiation, 105
 serotonin, 104
 vagotomy, 89
 effect on
 alveolar-capillary tissue barrier in animals, 51
 control of respiration, 60
 lung volumes, 57
 pulmonary function, 56
 pulmonary gas exchange, 58
 pulmonary mechanics, 57
 ganglionic blocking drugs, 87
 hypophyseal-adrenocortical interaction, 83
 biochemical studies, 84
 histological studies, 84
 inert gas, respired, role of, 101
 influence of
 sex hormones, 92
 thyroid activity, 91
 mechanisms, 79-109
 mitochondrial changes in the lung, 48
 pathological changes
 morphological techniques of study, 49, 50
 qualitative studies, 49
 reversibility during recovery, 53
 sequence of, 49
 serological techniques of study, 49, 50
 pathology, 39-56
 exudative phase, 54, 56
 in animals, 39-54
 in man, 54-56
 in newborn, 55
 proliferative phase, 54, 56
 physical findings, 62
 post-mortem changes in animals, 42
 protective influence of
 adrenalectomy, 84
 hypophysectomy, 83
 pulmonary edema, 43
 chemical composition of fluid, 44
 mechanism of formation, 44
 pulmonary hyaline membranes, 45
 extra-uterine respiration factor, 46
 mechanical factors contributing to development, 46
 pathogenesis of formation, 45
 variation among species, 45
 pulmonary surfactant
 lipid composition, 95
 reduction of concentration, 93
 role, 93, (table), 94
 pulmonary vascular changes, 47
 radiological changes, 62
 in newborn infants, 63
 rate of development, 63
 influence of respired inert gas, 102
 influential factors (tables), 109, 110
 modification, 111
 rate of recovery, 113
 resistance to
 acquired, 73
 avian species, 77
 cold-blooded animals, 77
 inherent, 77
 signs, 61
 sodium bicarbonate administration, 100
 sodium lactate administration, 100
 sympatho-adrenomedullary interaction, 86
 symptoms, 62
 tolerance to, 63
 variation among species, 39, 41
 Pulmonary surface activity
 effect of prolonged exposure to hyperoxia (table), 94
 Reserpine
 effects on common carotid occlusion pressor reflex, 300; (table) 301
 hypotensive potency, 299; (table), 300
 Seevers, Maurice H. (*See* Domino, Hardman and Seevers), 317
 (*See* Hardman, Domino and Seevers), 295
 Sex hormones
 influence in pulmonary oxygen toxicity, 92
 Synhexyl
 Comparison with Δ^9 - and Δ^8 -tetrahydrocannabinols by smoking, 349

Synhexyl—(Continued)

- oral dose
 - clinical syndromes, 349; (table), 352
 - comparison with Δ^9 -tetrahydrocannabinol, 349
 - physiological changes, 349
 - symptoms, 349
 - syndromes from smoking (table), 354

Tetrahydrocannabinol

- absorption, 274
 - preparation for, 275
- biological disposition, 273–278
- biotransformation (reactions scheme), 276
- cannabinoids and isomers and homologues, 351
- distribution, 275
 - inhalation *vs.* intraperitoneal route, 275
- effects on central nervous system, 285, 292
- excretion, 276
- intraperitoneal administration, 275
- intravenous administration, 275
- metabolism, 275
- metabolites, biological activity of, 277
- pharmacology
 - behavioral, 285–294
 - general, 285–294
- solvent systems for formulating drugs, 285
- structural formula, 297
- synthetic compound with misplaced double bond (1940 vintage), 265
- synthetic derivatives
 - behavioral responses, 298
 - cardiovascular pharmacology, 299–305
 - central nervous system actions, 317–336
 - DMHP, 295
 - drug interactions, 305–307
 - effects on spinal reflexes, 317
 - electroencephalic alterations, 317
 - MOP, 295
 - NAP, 295
 - pharmacological actions, 295–315
 - temperature regulation, 307–310
 - tolerance development, 310

Tetrahydrocannabinol, Δ^6 -

- comparison with synhexyl and Δ^9 -tetrahydrocannabinols by smoking, 349
- syndromes from smoking, 349; (table), 354

Tetrahydrocannabinol, Δ^8 -

- albumin suspensions, 285
- mouse hot-plate test (table), 287
- toxicity of (table), 286

analgesic activity

- abdominal-stretching test, 286
- mouse hot-plate test, 286; (table), 287
- antinociceptive activity, 286
- solubility properties, 271
- synthesis, 270, 271
- tolerance, in pigeons, 289

Tetrahydrocannabinol, Δ^9 -

- active constituent of cannabis, 339
- acute toxicity (tables), 280
- albumin suspension, 285
 - mouse hot-plate test (table), 287
 - toxicity of (table), 286
- analgesic activity, 285
 - abdominal-stretching test, 286
 - mouse hot-plate test, 286; (table), 287
 - mouse tail-flick test (table), 287
- antinociceptive activity, 286
- biphasic action, 283–284
- combined with
 - ethanol, 280, 282, 283
 - hexobarbital, 280, 281
- comparison with
 - dextroamphetamine, 349
 - ethanol, 349
 - LSD, 349
 - synhexyl and Δ^6 -tetrahydrocannabinol by smoking, 349
- cross tolerance with
 - DMHP in pigeons, 311
 - synhexyl in pigeons, 311
- disposition in man, 371
 - chronic marihuana users, 371
 - drug naive subjects, 371
- distribution in marihuana smoke, 274
- dose, problems in determination of, 349
- dose-effect relationships
 - heart rate, 343
 - mental function, 339, 343
 - motor function, 339, 343
 - pulse rates, 339, 343
 - pulse rate, magnitude and duration, 339, 344
- dose-response analysis, 339
 - pulse rate, 339
 - subjective response data, 339
- effect on
 - blood pressure, 286, 287, 288
 - body temperature, 283
 - cardiovascular parameters, 286, 288
 - conditioned behavior, 317
 - heart rate, 283
 - key pecking rates in pigeons, 289–293
 - mental functioning, 339

- respiratory parameters, 287, 288
 - respiratory rate, 283
 - excretion in man, 371
 - homologues and, future studies of, 349
 - hypothermic response, duration, 309
 - inhalation, psychological effects of, 371
 - initial phase of use, fate during (table), 375
 - intragastric injection, 280
 - intraperitoneal injection, 279
 - intravenous injection, 279
 - metabolism, 371
 - microsomal enzyme induction, 282
 - occurrence in marihuana, 268
 - oral dose
 - clinical syndromes, 349; (table), 352
 - comparison with synhexyl, 349
 - physiological changes, 349
 - psychological effects, 371
 - symptoms, 349
 - time course for psychic effects, 378
 - plasma levels after injection of ¹⁴C- Δ^9 -THC, 372, 374
 - plasma levels of ¹⁴C- Δ^9 -THC after oral administration of Δ^9 -THC and ¹⁴C- Δ^9 -THC, 378
 - radioactivity
 - after injection of ¹⁴C- Δ^9 -THC, 372, 374
 - ether-extractable (table), 375
 - extraction from feces (table), 377
 - extraction from urine (table), 377
 - volumes of distribution (table), 375
 - radiohistogram of thin-layer chromatography of Δ^9 -THC extracted from plasma, 373
 - sleeping time enhancement, 282
 - solubility properties, 271
 - syndromes from smoking (table), 354
 - synhexyl and
 - perceptual syndromes (table), 352
 - psychic syndromes (table), 352
 - somatic syndromes (table), 352
 - time course of clinical syndromes, 349; (table), 352
 - synthesis, 270, 271
 - tolerance
 - in dogs, 291
 - in pigeons, 289, 293
 - in rats, 291
 - toxicity, animal studies, 279-284
 - volume of distribution (table), 375
- Truitt, Edward B., Jr. Biological disposition of tetrahydrocannabinols, 273
- Waller, Coy W. Chemistry of marihuana, 265
- Way, E. Leong. Cannabis prelude, 263
- Wurtman, Richard J. (See Pohorecky and Wurtman), 1

2000 MUNICIPAL...
Prison...
2000

2327-55-1⁹